Craig S. Rosenfeld

Collaborative Medicinal Development LLC engages in the development of innovative therapies for neurodegenerative diseases and cancer. It offers CuATSM drug and clinical trials for ALS and Parkinson’s disease. The company is headquartered in Mill Valley, CA.

Medical City Dallas Hospital, Inc. engages in the provision of health care services. It specialize in the care of children, women, and adults, as well as the heart and spine. The company is headquartered in Dallas, TX.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC.

The Vaccine Co. develops therapeutic vaccines for the treatment of leukemias and other types of cancers. Its products include Proteinase 3 PR1 peptide vaccine, Proteinase 3 PR1 peptide vaccine, and Myelodysplastic Syndrome. The company was founded by Jeffrey Molldrem, Ronald B. Garren, Gregory C. Thayer, and Craig S. Rosenfeld in 2003 and is headquartered in San Francisco, CA.

SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA.